Comparing K2M Group Holdings (KTWO) & Its Competitors
K2M Group Holdings (NASDAQ: KTWO) is one of 80 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its rivals? We will compare K2M Group Holdings to similar businesses based on the strength of its dividends, risk, institutional ownership, earnings, profitability, analyst recommendations and valuation.
This table compares K2M Group Holdings and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|K2M Group Holdings||-16.22%||-16.02%||-10.73%|
|K2M Group Holdings Competitors||-126.29%||-96.13%||-11.23%|
Risk & Volatility
K2M Group Holdings has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, K2M Group Holdings’ rivals have a beta of 1.00, indicating that their average stock price is 0% more volatile than the S&P 500.
Valuation and Earnings
This table compares K2M Group Holdings and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|K2M Group Holdings||$236.63 million||-$41.66 million||-19.83|
|K2M Group Holdings Competitors||$975.11 million||$120.37 million||213.71|
K2M Group Holdings’ rivals have higher revenue and earnings than K2M Group Holdings. K2M Group Holdings is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
99.9% of K2M Group Holdings shares are held by institutional investors. Comparatively, 64.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 5.8% of K2M Group Holdings shares are held by company insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for K2M Group Holdings and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|K2M Group Holdings||0||0||8||1||3.11|
|K2M Group Holdings Competitors||205||1231||2678||94||2.63|
K2M Group Holdings presently has a consensus price target of $25.13, suggesting a potential upside of 31.96%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.00%. Given K2M Group Holdings’ stronger consensus rating and higher probable upside, equities analysts clearly believe K2M Group Holdings is more favorable than its rivals.
K2M Group Holdings beats its rivals on 9 of the 12 factors compared.
About K2M Group Holdings
K2M Group Holdings, Inc. is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. Its products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. As of December 31, 2016, its product portfolio consisted of 83 product lines that are used in complex spine, minimally invasive surgery (MIS) and degenerative surgeries. Its technologies include EVEREST, MESA, Rail 4D, Quicket Deformity, CASCADIA, CAPRI, SERENGETI, RAVINE and tifix. Its degenerative spine technologies are used to treat degenerative spine disorders and include products, such as cervical, thoracic and lumbar spinal fusion devices and interbody devices.
Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.